Veracyte Q2 2026: GAAP profit, 25% EPS beat, and raised guidance

As seen on the 24/7 Wall St. homepage on July 30, 2026.

VCYT Veracyte
Q2 2026
EPS
$0.54
est $0.43 +25.1%
Revenue
$150M
est $144M +4.0%

Veracyte swung to GAAP profitability while crushing EPS estimates by 25% in Q2, powered by 20% growth in Decipher Prostate and raised full-year guidance to reflect 14-15% revenue growth.

Continue ReadingShow less

Veracyte reported Q2 2026 earnings per share of $0.54, clearing the consensus estimate of $0.43 by roughly 25% and marking the company's return to GAAP profitability. Revenue came in at $150.3 million, about 4% ahead of the $144.5 million analysts had penciled in, with Decipher Prostate — the company's flagship genomic test for prostate cancer — delivering 20% growth as a key driver.

The beat extended a run of consistent outperformance: Veracyte has topped EPS estimates in each of the past eight reported quarters, with the gap between reported and estimated figures widening noticeably over the last year. The Q2 2026 EPS of $0.54 also represents the highest reported figure in that eight-quarter span, suggesting the profitability improvement is not a one-quarter anomaly.

Disclosure

1 INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA( www.finra.org )/SIPC( www.sipc.org ). 2 The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts. 3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. 4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.

SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now. (Sponsor)

Management followed the strong quarter by raising full-year guidance to reflect revenue growth of 14% to 15%, a signal that the company expects the Decipher Prostate momentum and broader portfolio performance to carry through the rest of 2026. Investors will be watching whether subsequent quarters can sustain the margin expansion that made GAAP profitability possible this period.

Mentioned: VCYT